LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
LAVA Therapeutics (Nasdaq: LVTX) has announced it will present clinical data for LAVA-051 during the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022. The presentation will focus on the mechanism of action of LAVA-051, a bispecific gamma delta T cell engager, confirming pharmacodynamics in a clinical setting. Chief Medical Officer Benjamin Winograd will present the findings on November 11, 2022.
LAVA’s Gammabody™ platform aims to treat solid and hematological malignancies.
- Presentation of LAVA-051 data at a major oncology event indicating progress in clinical development.
- Focus on the mechanism of action in a clinical setting suggests potential efficacy.
- Risks associated with clinical trial outcomes and regulatory approvals could impact future developments.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the Company will present data demonstrating on-mechanism pharmacodynamics for LAVA-051 in the clinic during the Society for Immunotherapy of Cancer’s 37th Annual Meeting, taking place in Boston, Massachusetts and virtually from November 8-12, 2022.
The details of the poster presentation session are as follows:
Abstract #: 686
Abstract Title: Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting
Session Title: Cellular Therapies + Bispecifics
Session Date: Friday, November 11, 2022
Session Time: 9:00 a.m.–8:30 p.m. EST/3:00 p.m.–2:30 a.m. CET
Presenter: Benjamin Winograd, M.D., Ph.D., chief medical officer, LAVA Therapeutics
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematological malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including with respect to the company’s anticipated growth and clinical development plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. The COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACTS
Investor Relations
ir@lavatherapeutics.com
Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com
FAQ
What will LAVA Therapeutics present at the Society for Immunotherapy of Cancer’s 37th Annual Meeting?
When is the LAVA-051 presentation scheduled?
What is the significance of LAVA-051's presentation?
What platform does LAVA Therapeutics use for its drug development?
